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University Hospital's (NSUH) Center for International Blood
and Marrow Transplant Research (CIBMTR) data to describe
the relapse and survival of our diffuse large cell lymphoma
patients in second remission / response undergoing high
dose chemotherapy and autologous stem cell transplantation
from December 2007 to March 2012.
Our primary aimwas to evaluate overall and progression-
free survival at 100 days and 1 year post transplant.
Descriptive statistics (mean, standard deviation, frequencies
and proportions) were calculated for demographics and
clinical factors. The Kaplan-Meier product-limit method was
used to estimate OS and PFS. Subjects inwhich the outcomes
of interest (death or progression) were not observed were
considered censored using their last date of follow-up.
This analysis consisted of 29 patients; mean age 57.85
years. The 100-day and one year overall survival rates were
89.66% and 67.81%, respectively. The 100-day and one year
progression free survival rates were 78.57% and 73.33%,
respectively. Among those patients who died, the primary
causes of death were bacterial infection, recurrence of
primary disease, and cardiac failure.
These outcomes appear comparable to those provided by
the Center for International Blood and Marrow Transplant
Research. Thus allowing us to conclude that Augmented CBV
is a viable preparative regimen for patients with relapsed
diffuse large cell lymphoma undergoing autologous stem cell
transplantation.243
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Sarcopenia is a state of abnormally low muscle mass that
is associated with more treatment-related complications,
shorter time to recurrence or progression, and shorter overall
survival in patients with different cancers, including
lymphoma, pancreatic, lung, and breast cancer. Sarcopenia is
a potentially modiﬁable host factor that can be easily and
reliably obtained from routine computerized tomography
(CT). The objective of this study is to determine whether
sarcopenia impacts transplant-related outcomes in patients
undergoing autologous and allogeneic hematopoietic stem
cell transplantation (HSCT) for Hodgkin's lymphoma (HL) or
non-Hodgkin's lymphoma (NHL). Patients transplanted
between 6/2005 and 6/2012 at the University of Michigan
BMT Program were eligible for inclusion if a CT of the
abdomen was performed within 60 days prior to HSCT.
Cross-sectional area and density of the psoas muscles at the
level of the fourth lumbar vertebra were calculated. Lean
psoas muscle mass accounting for fatty inﬁltration was
determined using algorithms programmed in the Analytic
Morphomics Lab at the University of Michigan.
Results: Total psoas area and lean psoas area were calculated
for 121 autologous transplant patients who met inclusion
criteria. The median total psoas area/height was 1255.2
mm2/m and the median lean psoas area/height was 977.4
mm2/m. After controlling for age and gender, the hazard ratio
for non-relapse mortality (NRM)was 0.79 (C.I. 0.60,1.05), P¼.088 for every 100mm2/m increase in total psoas area/height
and 0.75 (C.I. 0.55, 1.04), P ¼ .099 for every 100 mm2/m
increase in lean psoas area/height. Patients were then
divided into tertiles for total psoas area/height and lean
psoas area/height. Since only one NRM event was observed
among included women and occurred in a woman in the
lowest tertile for total psoas area/height and lean psoas area/
height, the tertile anlaysis was conducted in only men.
Among all included men, a greater NRM was seen in the
patients in the bottom two tertiles, compared to the tertile
with the greatest muscle mass and can be observed in the
attached ﬁgure (P ¼ .02 and P ¼ .03 for a log-rank test of the
lowest and middle tertile respectively). In the 43 allogeneic
transplants, sarcopenia had no impact on outcome.
Conclusion: Patients with a greater degree of pre-transplant
sarcopenia who underwent an autologous HSCT for NHL or
HL had a greater risk of NRM than those with greater muscle
mass. CT-determined psoas muscle mass may be a valuable
addition to comorbidity indices used to guide optimal
treatment selection and serve as a potentially modiﬁable
host factor to improve transplant-related outcomes. This
difference was not noted in the allogeneic transplant pop-
ulation, where a different and more complex set of compli-
cations may come into play, although this requires
conﬁrmation in a larger sample.
244
Autologous Hematopoietic Stem Cell Transplantation in
Light Chain Amyloidosis (AL) With Renal Involvement
A. Megan Cornelison, Simrit Parmar, Qaiser Bashir, Nina Shah,
Josh Howell, Chitra Hosing, Uday Popat, Richard E. Champlin,
Muzaffar Qazilbash. UT MD Anderson Cancer Center,
Houston, TX
Background: Immunoglobulin light chain amyloidosis (AL)
is characterized by deposition of insoluble ﬁbrils composed
of immunoglobulin light chains, causing progressive organ
dysfunction. Renal involvement is seen in 50% of cases of AL,
which, if left untreated, progresses to end-stage renal disease
(ESRD).
Methods: We performed a retrospective analysis in 75
patients (pts) with AL with renal involvement who under-
went high-dose chemotherapy and autologous hematopoi-
etic stem cell transplantation (auto-HCT) at our institution
between 1999 and 2011. Fifty-ﬁve of these AL pts had
renal involvement, as deﬁned by the International
Consensus Criteria (Ref. Gertz M et al. AJH 2005). Primary
objectives were to assess hematologic and organ response,
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lation between hematologic and organ response.
Results:Median age at auto-HCTwas 59 years (range, 41-74).
Median time from diagnosis to auto-HCT was 6.6 months
(2.2-121.9). Additional visceral organs involved were: heart 5
pts (9%), GI tract 3 pts (5%), peripheral nerves 1 pt (2%) and
liver 5 pts (9%). Median baseline 24-hour proteinuria was
5.055 grams (range, 0.17- 27.85 grams). All pts received
melphalan or melphalan-based combinations as their
preparative regimen.Median time to neutrophil engraftment
was 10 days (range, 7-15). Median follow up from auto-HCT
was 24.5 months (range, 0.4-132). Six pts died of non-relapse
causes with a non-relapse mortality (NRM) at both 100 days
and 1 year of 10.9%. Fifty pts were evaluable for a hemato-
logic response, while 5 patients were inevaluable due to
early death. Eight pts (16%) achieved complete remission
(CR), 10 (20%) achieved a very good partial remission (VGPR)
and 21 (42%) achieved a partial remission (PR), with an
overall response rate of 78%. Organ response was evaluated
at 6, 12, and 24 months, and was deﬁned as a 50% decrease
in total proteinuria over 24 hours without an increase of
25% of serum creatinine. Organ response was demon-
strated in 8 (17%) of 47 evaluable pts at 6 months, in 11 (29%)
of 38 evaluable pts at 12 months, and in 12 (44%) of 27
evaluable pts at 24 months, respectively. Organ responses at
last follow up were seen in 12 of 28 pts with > hematologic
PR and 0 of 11 pts with < hematologic PR (P ¼ .008). Two pts
who were hemodialysis-dependent pre auto-HCT remained
on dialysis after the auto-HCT. Median PFS and OS were 43.1
and 69.9 months, respectively. Kaplan-Meier estimates of 3-
year PFS and OS were 62% and 73%, respectively (Figure 1). At
the time of last follow-up, 37 pts (67%) were alive and in
remission.
Conclusions: High-dose melphalan and auto-HCT is associ-
ated with durable hematologic and organ response, and long
OS in patients with AL and renal involvement. Achievement
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Minneapolis, MNCD20 is a trans-membrane protein expressed onmature B
cells through all stages of their development. However, its
expression is down regulated at the point of differentiation
into plasma cells and expressed only in 16-22% of mature
plasma cells. CD20 expression on plasma cells has been
described with both favorable prognosis in association with
translocation t(11;14) and unfavorable prognosis in associa-
tion with plasma cell leukemia. The incidence of CD20
expression on plasma cells from patients with relapsed/
refractory multiple myeloma is not well stated in literature
and not routinely done in this patients' population. Addi-
tionally, it is not known if CD20 represents a primary aberrant
expression in newly diagnosed cases of multiple myeloma or
possibly represents a secondary genetic change at the time of
relapse related to hypothesized myeloma stem cells.
In order to study the above questions, we retrospectively
reviewed the medical records of 92 patients with symp-
tomatic MM who underwent ASCT between January 2008
and December 2011. As of July 2012, 38 patients have
relapsed. Bone marrow biopsy and ﬂow cytometry results
were available for 33 patients at time of diagnosis and
relapse. CD20 expression was positive on plasma cells by
ﬂow cytometry in 11 out of 33 patients (33%) at time of
relapse. Interestingly, CD20 expression at diagnosis was
negative in 4 out of these 11 patients. This up-regulation in
CD 20 expressionwas associatedwith clonal evolution in two
patients (deletion-17 and complex hypo-diploid cytogenetic,
respectively). Conﬁrmatory immune-histochemical staining
for CD20 was positive only in 2 of these 4 patients.
Conclusion: CD20 expression on plasma cells at time of
relapse/progression can occur in one third of patients with
multiple myeloma and may provide an additional thera-
peutic target. The cause of discrepancy between CD20
expression by ﬂow cytometry and immune-histochemical
staining is unclear and suggests that the two methods may
be complementary for a comprehensive evaluation of CD20
expression in multiple myeloma. CD20 up-regulation in
patients with relapsed/refractory myeloma who were
previously CD20 negative at diagnosis may represent
a secondary genetic event heralding a more aggressive
disease. Future prospective studies evaluating CD20 expres-
sion on plasma cells at different stages of disease progression
may optimize the timing for anti-CD20 therapy while har-
nessing the concept of colonogeneic myeloma stem cells.246
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Background: AL is characterized by the production of
monoclonal light chains which misfold, deposit in various
organs, including the heart, and cause early death. High dose
melphalan with SCT results in high hematologic response
(HR) rates and is standard treatment for eligible patients.
Achieving a CR to SCT results in extended EFS and OS. We
have studied novel agents as consolidation following
